Tectonic Therapeutic is the latest venture undertaken by Harvard’s serial entrepreneur Timothy Springer, who co-led the series A round.
Tectonic Therapeutic, a US-based biotechnology spinout of Harvard University, has collected $80m in its series A round co-led by Prof Timothy Springer, one of its co-founders and faculty member at Harvard Medical School.
Vida Ventures and Polaris Partners co-led the round, which also attracted EcoR1 Capital.
Founded in 2019, Tectonic is working on G-protein-coupled receptors (GPCR)-targeted therapies. The proteins are a popular drug target due to their involvement in numerous bodily functions but their potential remains mostly untapped…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
